<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5679">
  <stage>Registered</stage>
  <submitdate>24/03/2014</submitdate>
  <approvaldate>24/03/2014</approvaldate>
  <nctid>NCT02097082</nctid>
  <trial_identification>
    <studytitle>Treatment of SFA Lesions With 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System</studytitle>
    <scientifictitle>An Evaluation of the 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions</scientifictitle>
    <utrn />
    <trialacronym>SPRINT</trialacronym>
    <secondaryid>480-SFA2013-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Arterial Disease</healthcondition>
    <healthcondition>Intermittent Claudication</healthcondition>
    <healthcondition>Vascular Diseases</healthcondition>
    <healthcondition>Cardiovascular Diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - STANZA Drug-eluting resorbable Scaffold

Experimental: STANZA Drug-eluting Resorbable Scaffold - Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold


Treatment: devices: STANZA Drug-eluting resorbable Scaffold


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Patency by Ultrasound - Patency measured by duplex ultrasound with =50% restenosis (Peak Systolic Velocity Ratio (PSVR = 2.4).</outcome>
      <timepoint>through 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Major Adverse Events - Freedom from all causes of death, emergent endovascular intervention or surgical intervention on the target limb, index limb amputation.</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Success - On a per patient basis, technical success without major adverse event (MAE) within 48 hours after the index procedure or at hospital discharge, whichever is sooner.</outcome>
      <timepoint>48 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Device Success - On a per device basis, the achievement of successful delivery and deployment of the study device at the intended target lesion and successful withdrawal of the delivery catheter.</outcome>
      <timepoint>Procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Technical Success - Technical success is defined on a per lesion basis, as the achievement of a final residual stenosis of = 30%.</outcome>
      <timepoint>Procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patency by Ultrasound - Patency measured by duplex ultrasound with =50% restenosis (PSVR = 2.4) based on core lab evaluation at 12 and 24 months.</outcome>
      <timepoint>12, 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patency by Angiography - =50% diameter stenosis determined by an angiographic core lab analysis of an angiogram performed at 12 months.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically Driven Target Lesion Revascularization (TLR) - Clinically Driven TLR is defined as symptomatic patients with:
Decrease in Ankle Brachial Index (ABI) &gt; 0.15 and Increase in Rutherford Becker Category = 1 from post procedure assessment and &gt;50% stenosis by angiography.</outcome>
      <timepoint>6,12, 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical Intervention on the target limb, index limb amputation</outcome>
      <timepoint>3,6,12, and 24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          1. Age &gt; 18 years.

          2. De novo stenotic lesion(s) in the superficial femoral artery located at least 1 cm
             distal to the femoral bifurcation and &gt; 5 cm above the joint space of the knee.

          3. Patient has symptomatic intermittent claudication affecting at least the target leg
             (Rutherford Class 2-3). Patients should have first received conservative medical
             management of their symptoms prior to study inclusion. The symptoms can be bilateral.

          4. The study patient has been informed of the nature of the study, agrees to its
             provisions and has provided written informed consent as approved by the ethics
             committee of the respective clinical site.

          5. The study patient agrees to comply with all required post-procedure study
             requirements.

        Baseline Inclusion Criteria

          1. Reference vessel diameter (RVD) 5.0 -6.0 mm measured by an objective measurement such
             as online Quantitative Vessel Analysis (QVA).

          2. Target lesion length = 90 mm; total occlusion length &lt; 40 mm.

          3. Target lesion has a =70% diameter stenosis.

          4. Angiographic evidence of at least one runoff vessel to the ankle/foot without
             hemodynamically significant stenosis (&gt;50% diameter stenosis) that does not require
             any treatment within 3 months of the index procedure.

          5. Procedural access can be accomplished via contralateral vascular access or if
             antegrade access no closure device can be utilized and closure has to occur via manual
             pressure.

          6. Patent common and external iliac: TASC A &amp; B iliac lesions may be treated at the time
             of index procedure (before treatment of the target lesion) if residual stenosis is
             =30%.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          1. Previous vascular surgery/endovascular treatment of the target lesion.

          2. Re-vascularization of target vessel within 30 days of study procedure.

          3. Critical limb ischemia defined as Rutherford Becker Category 4-6.

          4. Known coagulation disorders or intolerance or allergies to aspirin, clopidogrel or
             ticlopidine, heparin, any scaffold components, contrast agents which cannot be
             adequately pre-medicated.

          5. Life expectancy =12 months.

          6. Planned procedure that necessitates the discontinuation of antiplatelet medications
             used in conjunction with the investigational device within 3 months post-procedure.

          7. Inability to walk due to orthopedic or other nonvascular complications.

          8. Pregnancy or breast feeding or patient desires to become pregnant.

          9. Non-atherosclerotic lesion (e.g. vasculitis).

         10. Renal insufficiency (serum creatinine level &gt; 220 Âµmol/L or &gt; 2.5 mg/dl, or patient is
             on dialysis).

         11. Patient has medical condition(s) which could affect study assessments or may adversely
             affect the safety and/or success of the study treatment.

         12. Active systemic infection or lower limb infection of any nature.

         13. White Blood Cells (WBC) = 3,000 cells/mm3.

         14. Myocardial infarction within 30 days prior to the study procedure.

         15. Stroke within 90 days prior to the study procedure.

         16. Uncontrolled atrial fibrillation.

         17. Currently participating in an investigational drug or another device study. Note:
             Trials requiring extended follow-up for products that were investigational, but have
             since become commercially available, are not considered investigational trials.

         18. Prior use of paclitaxel-eluting products in the target limb less than 6 months prior
             to index procedure.

         19. Patient has known unstable angina.

        Baseline Exclusion Criteria

          1. Target lesion treatment with a drug eluting balloon.

          2. Target lesion treatment with atherectomy, laser, or cryoplasty (use of a cutting or
             scoring balloon is permitted prior to scaffold implantation only).

          3. Suspicion for or evidence of subintimal passage of guidewire.

          4. Severely calcified lesion(s).

          5. Target lesion which, based on two angiographic orthogonal views, exhibit a persistent
             balloon deformity during pre-dilatation with a nominally sized balloon.

          6. Target vessel (superficial femoral artery) has an angiographically significant (&gt; 50%
             diameter stenosis) lesion located distally or proximally to the target lesion.

          7. Acute embolic complication following pre-dilatation.

          8. Target vessel contains an acute thrombus.

          9. Aneurysm in target vessel or co-existing clinically significant aneurysmal disease of
             the abdominal aorta, iliac or popliteal arteries.

         10. Intervention in the infra-inguinal arteries outside of the target lesion.

         11. Planned procedure within 30 days after the index procedure.

         12. Positive pregnancy test for females of child bearing potential.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Wuerttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bavaria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Saxony</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>480 Biomedical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold
      (DRS) system for the treatment of patients with obstructive superficial femoral artery
      disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02097082</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Holden, MD</name>
      <address>Auckland City Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Wendy Naimark, PhD</name>
      <address />
      <phone>617-393-4600</phone>
      <fax />
      <email>wnaimark@480biomedical.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>